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Abstract: Since the pioneering work of John Gofman in the 1950s, our understanding of high 
density lipoprotein cholesterol (HDL-C) and its relationship to coronary heart disease (CHD) 
has grown substantially. Numerous clinical trials since the Framingham Study in 1977 have 
demonstrated an inverse relationship between HDL-C and one’s risk of developing CHD. Over 
the past two decades, preclinical research has gained further insight into the nature of HDL-C 
metabolism, speciﬁ  cally regarding the ability of HDL-C to promote reverse cholesterol transport 
(RCT). Recent attempts to harness HDL’s ability to enhance RCT have revealed the complex-
ity of HDL-C metabolism. This review provides a detailed update on HDL-C as an evolving 
therapeutic target in the management of cardiovascular disease.
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Introduction
In the early 1900s, a German chemist named Adolph Windaus determined atheromatous 
plaque from human aortas contained 20-fold higher concentrations of cholesterol than 
normal aortas. Soon after, the Russian pathologist Nikolai Anitschov strengthened 
this observation by feeding rabbits a high-cholesterol diet and creating the ﬁ  rst animal 
model of atherosclerosis (Khavkin et al 1975; Vance et al 2000). In 1955, a biophysi-
cist named John Gofman used ultracentrifugation to separate plasma lipoproteins by 
density and correlated risk of myocardial infarction (MI) with elevated low-density 
lipoprotein cholesterol (LDL-C) levels. Henceforth, the ‘lipid hypothesis’ proposed 
that elevated LDL-C, elevated triacylglycerols (TG), and low levels of high density 
lipoprotein cholesterol (HDL-C) were causally associated with an increased risk of 
coronary heart disease (CHD) (Soloff 1998).
In 1977, the Framingham Study showed that elevated LDL-C and reduced HDL-C 
levels independently predict one’s risk for developing cardiovascular disease (Gordon 
et al 1977). Since the ﬁ  rst Adult Treatment Panel (ATP) recommendations in 1988 
[Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol 
in Adults (Adult Treatment Panel II) 1993], guidelines have increasingly focused on 
aggressive management of elevated LDL-C in populations at risk for CHD. According 
to the National Cholesterol Education Panel (NCEP) ATP III guidelines published 
in 2001, patients with established CHD, non-coronary atherosclerosis, diabetes mel-
litus, or greater than two major cardiac risk factors with a calculated Framingham 
risk score of greater than 20% should have an LDL-C goal of less than 100 mg/dL 
[Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in 
Adults (Adult Treatment Panel III) 2001]. Subsequently, the Heart Protection Study 
(HPS) (MRC/BHF Heart Protection Study 1999) and Pravastatin or Atorvastatin Vascular Health and Risk Management 2008:4(1) 40
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Evaluation and Infection Therapy (PROVE-IT) (Cannon 
et al 2004) trial reported incremental 22% and 16% reduc-
tions, respectively, in the risk of cardiovascular events with 
LDL-C levels lowered below 100 mg/dL. Based on these 
data, an “optional” target of therapy focusing on aggressive 
LDL-C lowering less than 70 mg/dL for patients with known 
coronary disease or CHD equivalent status has been proposed 
(Grundy et al 2004).
However, despite lowering LDL-C to levels recom-
mended by the NCEP in 90% of treated patients, an overall 
reduction of only 20%–35% in the rate of cardiovascular 
events has been observed in randomized trials (Shah et al 
2002). Moreover, nearly 15% of patients with acute myocar-
dial infarction (MI) have LDL-C levels less than 100 mg/dL 
at presentation (Forrester et al 2005), suggesting that previ-
ously cited LDL-C targets remain too high or the beneﬁ  t of 
very aggressive LDL-C lowering is quite limited. The Treat-
ing to New Targets (TNT) trial (LaRosa et al 2005) showed 
a 2.2% absolute and a 22% relative risk reduction for major 
cardiovascular events in patients receiving high dose com-
pared to low dose atorvastatin. The mean LDL-C levels were 
77 mg/dL in the high dose statin group versus 100 mg/dL in 
the low dose statin group. Thus, while great emphasis has 
been placed on the importance of LDL-C lowering in CVD 
risk reduction, there is growing interest directed at raising 
HDL-C levels for further risk reduction.
At present, no approved therapies increase HDL-C 
levels by any comparable magnitude to therapies designed 
to lower LDL-C levels. This review provides a detailed 
update on HDL-C as a therapeutic target for CVD risk 
reduction.
HDL-C and coronary heart disease
Substantial epidemiologic evidence suggests a negative lin-
ear correlation between HDL-C levels and the incidence of 
CHD. First proposed by Barr and colleagues in 1951 (Barr 
et al 1951), an inverse relationship between HDL-C and 
cardiovascular disease was not well established until the 
Framingham study in the 1970s (Gordon et al 1997). This 
analysis of 2815 men and women aged 49–82 years identi-
ﬁ  ed HDL-C as a powerful risk factor inversely associated 
with the incidence of CHD. Similarly, in the early 1980s, the 
Prospective Cardiovascular Munster (PROCAM) (Kannel 
1983) study evaluated 4559 male participants aged 40–64 
years and found a strong negative linear correlation between 
the incidence of CAD and HDL-C levels (CHD risk ratio 
of 4.0 for HDL-C  25 mg/dL versus 1.0 for HDL-C  65 
mg/dL, p   0.001).
Data from four studies (Framingham Heart Study, the 
Lipid Research Clinic Prevalence Mortality Follow-up Study, 
Lipid Research Clinic Primary Prevention Trial, and Multiple 
Risk Factor Intervention Trial) estimate a 2% reduction in 
cardiovascular risk for every 1 mg/dL increase in serum 
HDL-C (Gordon et al 1989; Castelli et al 1992; Multiple 
Risk Factor Intervention Trial 1982). Individuals with low 
HDL-C ( 40 mg/dL in men and  50 mg/dL in women) are 
at increased risk of CVD (Miller et al 1977), restenosis fol-
lowing coronary balloon angioplasty (Shah and Amin 1992) 
and cardiovascular death (Wilson et al 1988).
One of the ﬁ  rst trials demonstrating the beneﬁ  t of raising 
HDL-C and lowering TG levels in individuals with low 
baseline HDL-C levels was the Helsinki Heart Study (HHS) 
(Manninen et al 1992), in which 4081 men with dyslipidemia 
were randomized to receive gemﬁ  brozil (600 mg twice 
daily) or placebo. At 5 years of follow-up, gemﬁ  brozil 
therapy increased HDL-C levels by 11% and reduced total 
cholesterol (TC), LDL-C, and TG levels by 10%, 11%, and 
35% respectively. Gemﬁ  brozil therapy reduced the primary 
end point of cardiac death or non-fatal MI by 34% (27.3 vs 
41.4/1,000, p   0.02) with the greatest reduction found in 
patients with low HDL-C and high TG at baseline (Manttari 
et al 1990).
The Air Force/Texas Coronary Atherosclerosis Pre-
vention Study (AFCAPS/TexCAPS) (Downs et al 1998) 
compared treatment with lovastatin versus placebo for the 
prevention of a ﬁ  rst major coronary event in adults with 
average TC and LDL-C levels, but low baseline levels of 
HDL-C. Lovastatin decreased both TC and LDL-C levels by 
18% and 25%, respectively, while increasing HDL-C levels 
by 6%. After more than 5 years of follow-up, the absolute 
risk in the primary composite end point of fatal or non-fatal 
MI, unstable angina, or sudden cardiac death was reduced 
in absolute terms by 2.2% in men and 1.2% in women with 
a relative risk reduction of 37%. This study was the ﬁ  rst 
primary prevention study to show that individuals with 
HDL-C  40 mg/dL received the greatest beneﬁ  t, suggesting 
the lower cutpoint HDL-C of 35 mg/dL in ATP II should be 
raised to 40 mg/dL in ATP III. These clinical trials conﬁ  rm 
an increased risk associated with low serum levels of HDL-C 
and the beneﬁ  cial effects of pharmacotherapy in adults with 
low HDL-C in primary prevention.
Patients with manifest CHD also beneﬁ  t from raising 
HDL-C and lowering TG. The Veterans Affairs High-Density 
Lipoprotein Cholesterol Intervention Trial (VA-HIT) com-
pared treatment with gemﬁ  brozil versus placebo in more 
than 2500 men with established CHD, average LDL-C levels Vascular Health and Risk Management 2008:4(1) 41
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( 140 mg/dL), and low HDL-C levels ( 40 mg/dL). After a 
mean follow-up of 5 years, gemﬁ  brozil decreased TG levels 
by 31% and increased HDL-C levels by 6%, while levels 
of LDL-C remained quantitatively unchanged; there was a 
relative risk reduction of 22% (17.3% vs 21.7% p   0.006) 
in CHD death and non-fatal MI in the treatment group. 
Gemﬁ  brozil therapy was associated with a 24% relative risk 
reduction in the composite end point of nonfatal MI, stroke, 
and CHD death (p   0.001) (Rubins et al 2001).
The Scandanavian Simvastatin Survival Study Group 
(4S) was a large, randomized, placebo-controlled trial 
evaluating simvastatin (20–40 mg/day) in 4444 men and 
women aged 35–70 years over a median follow-up period 
of 5.4 years. Simvastatin therapy decrease TC and LDL-C 
(25% and 35%, respectively) and increased HDL-C by 8% 
compared to placebo. Simvastatin treatment resulted in a 
30% relative risk reduction in overall mortality (8.2% vs 
11.5%, p = 0.0003) and reduced non-fatal MI, ischemic heart 
disease death, and coronary revascularization (Scandinavian 
Simvastatin Survival Study Group 1994).
The Bezaﬁ  brate Infarction Prevention Study (BIPS) was 
a blinded, placebo-controlled trial of bezaﬁ  brate therapy in 
3122 patients with previous MI or angina pectoris and base-
line LDL-C  180 mg/dL, HDL-C  45 mg/dL, and TG  300 
mg/dL. At 5–7 years of follow-up, bezaﬁ  brate increased 
HDL-C more than 15% and decreased TG levels by 25%. 
The overall relative reduction in the primary end point of 9% 
was not statistically signiﬁ  cant; however, a 40% relative risk 
reduction was observed in patients with baseline TG  200 
mg/dL, suggesting ﬁ  brates may be beneﬁ  cial in patients with 
known CAD and elevated TG levels (Kaplinsky 1998).
Based on the epidemiologic data available, the NCEP ATP 
III guidelines raised the cut-point for low HDL-C levels from 
35 mg/dL to 40 mg/dL, thereby identifying a larger number of 
adults at risk for developing CHD. Current guidelines deﬁ  ne 
“high” HDL-C levels as above 60 mg/dL (Grundy et al 2004). 
The deﬁ  nition of “optimal” HDL-C will likely undergo further 
modiﬁ  cation as data becomes available.
HDL-C metabolism and reverse 
cholesterol transport (RCT)
By transporting excess cholesterol from peripheral cells 
to the liver for excretion in a process known as reverse 
cholesterol transport (RCT), HDL-C may retard the pro-
gression of atherosclerosis. In animal studies, exogenous 
infusions of HDL-C or apolipoprotein A-1 (Apo AI), the 
major apolipoprotein associated with HDL-C, prevents 
atherosclerosis from developing or progressing (Badimon 
et al 1990; Duverger et al 1996). Similar ﬁ  ndings have been 
reported in animal models of Apo AI gene over-expression 
(Dimayuga et al 1999). Harnessing this unique ability of 
HDL-C requires further insight into the basic mechanisms 
of HDL-C metabolism.
HDL-C metabolism involves numerous enzymes and 
unique nuclear transcription regulatory proteins intimately 
linked to other lipoproteins. HDL-C is a macromolecule 
containing lipids and proteins that transport water-insoluble 
fats in blood. A phospholipid (PL) monolayer containing 
free cholesterol (FC) and apolipoproteins (Apo) surrounds 
a non-polar lipid core containing FC and TG. Apo AI and 
AII are the major protein components of HDL-C. Apo AI 
is produced by the liver and intestines and constitutes 70% 
of HDL-C protein content. Apo AII is produced only by the 
liver and constitutes 20% of HDL-C protein content. While 
Apo AI is ubiquitously associated with HDL-C, Apo AII is 
found in about 60% of HDL-C molecules (Lewis et al 2005). 
Apolipoproteins serve as receptor ligands and enzymatic 
catalysts for all circulating liporoteins.
Clinical observations of premature CHD in patients with 
inherited disorders of metabolism resulting in low circulating 
HDL-C levels, such as homozygous Apo AI/CIII deﬁ  ciency 
and hypoalphaproteinemia support the association between 
low serum HDL-C levels and atherosclerosis (Forte TM 
1984). Conversely, individuals with inherited defects result-
ing in low serum HDL-C levels have variable or no premature 
CHD (eg, Tangier disease, Apo AI Milano, and familial 
lecithin:cholesterol acyltransferase (LCAT) deﬁ  ciency), 
highlighting the complexity of HDL-C metabolism (Miller 
et al 1990; Elkhalil et al 1997). Characterized in 1968 by 
Glomset, RCT can be divided into four phases (Glomset 
1968) (Figure 1).
Phase one: nascent HDL-C acquires 
free cholesterol
The nascent form of circulating HDL-C rich in Apo AI, 
termed discoidal pre-β HDL, removes FC and PL from 
peripheral cells throughout the body by interacting with 
a membrane associated protein ubiquitously expressed in 
peripheral tissues, known as ATP-binding cassette transporter 
1 (ABCA1). Pre-β HDL is rich in Apo AI and serves as a tem-
plate for the generation of lipid-rich HDL-C (Sviridov et al 
2002). Pre-β HDL is generated by either de novo secretion 
from hepatocytes or the intestinal mucosa, direct dissociation 
from chylomicrons and very low density lipoprotein (VLDL) 
mediated by lipoprotein lipase (LL), or as a by-product of 
HDL-C particle interconversion (Kwiterovich 1998).Vascular Health and Risk Management 2008:4(1) 42
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Once generated, pre-β HDL receives PL and FC from 
peripheral cells by associating with the surface protein ABCA1 
(Oram and Lawn 2001), which is expressed by the liver and 
intestinal mucosa. Patients with Tangier Disease, an autoso-
mal recessive disorder characterized by two non-functional 
ABCA1 alleles and extremely low levels of HDL-C, exemplify 
the signiﬁ  cance of ABCA1 in HDL-C metabolism (Bodzioch 
et al 1999). Heterozygous individuals with a partial reduction 
in functional ABCA1 have a corresponding 50% decrease in 
serum HDL-C levels (Marcil et al 1999).
Animal models further support the critical role of ABCA1 
in RCT. ABCA1-deﬁ  cient mice generated by targeted gene 
ablation in DBA-1J embryonic stem cells demonstrated a 
99.5% and 99.8% reduction in serum HDL-C and Apo AI 
levels, respectively. In this model, loss of ABCA1 correlated 
with increased accumulation of lipid-laden macrophages, an 
integral component of atherosclerotic plaque (McNeish et al 
2000). Conversely, overexpression of ABCA1 in transgenic 
mice is associated with increased TC, HDL-C levels, and Apo 
AI with enhanced cholesterol efﬂ  ux and reduced levels of 
atherogenesis (Brewer et al 2004). Finally, crossing trans-
genic mice overexpressing ABCA1 with athero-susceptible 
transgenic mice, such as LDL receptor (LDLr) or Apoli-
poprotein E knockout (KO) models, reduced atheromatous 
progression (Joyce et al 2003).
ABCG1 is another member of the ATP-binding cassette 
family that promotes efﬂ  ux of PL and FC from macrophages 
to mature HDL-C rather than pre-β HDL (Kennedy et al 2005) 
Macrophages deﬁ  cient in ABCG1 also have impaired FC efﬂ  ux 
and accumulate excess cholesterol (Out R 2006). Taken together, 
these data suggest that both ABCA1 and ABCG1 are potential 
therapeutic targets to raise HDL-C and promote RCT.
Transcription of both ABCA1 and ABCG1 is regulated by 
members of a steroid superfamily of nuclear receptors known 
as the Liver X receptor/Retinoid X receptor (LXR/RXR) 
heterodimer. When activated by oxysterols from FC this 
heterodimer stimulates ABCA1 and ABCG1 gene expression, 
thereby enhancing cholesterol efﬂ  ux (Vaughan and Oram 2005; 
Venkateswaran et al 2000). The heterodimer is also regulated 
by the activity of peroxisome proliferator-activated receptors 
(PPAR) α and γ, which are closely linked to insulin resistance 
and the metabolic syndrome (Anderson et al 2004). PPAR-α 
and PPAR-γ agonists have been shown to upregulate LXR and 
ABCA1 expression and promote macrophage cholesterol efﬂ  ux 
Figure 1 HDL-C mediated reverse cholesterol transport. Reverse cholesterol transport (RCT) can be divided into four phases. 1) transfer of free cholesterol (FC) to pre-b 
HDL via ABCA1, 2) esteriﬁ  cation of surface-associated FC by the enzyme Lecithin:acyl CoA Transferase (LCAT), 3) transfer of FC and triglycerides (TG) between HDL-C 
and Apo B-containing lipoproteins mediated by the enzyme cholesteryl ester transfer protein (CETP), and 4) uptake by the scavenger receptor B1 (SR-B1) and catabolism of 
mature HDL-C into bile or small HDL-C particles by hepatic lipase (HL). Apo B-containing lipoproteins can be acquired by the LDL-receptor (LDLr) for hepatic catabolism.
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(Schmitz et al 2002; Chawla et al 2001). Synthetic LXR agonists 
also promote cholesterol efﬂ  ux in vivo and promote regression 
of atherosclerosis in mice (Bruemmer and Law 2005).
Phase two: lecithin: acyl CoA 
transferase (LCAT) esteriﬁ  es free 
cholesterol
As FC is acquired from peripheral tissues, pre-β HDL 
matures from an incipient discoidal form into a larger 
spherical molecule. Newly acquired FC undergoes 
esterﬁ  cation to form cholesteryl esters (CE) which migrate 
to the center of the discoidal pre-beta HDL molecule. The 
spherical morphology of mature α-HDL-C promotes further 
HDL-C metabolism and cholesterol efﬂ  ux (Wang and Briggs 
2004). Cholesterol esteriﬁ  cation prevents transfer of FC back 
to the periphery, thereby potentiating further RCT.
Mediating this necessary step in HDL-C maturation is the 
enzyme LCAT, which is synthesized by the liver. Circulating 
LCAT esteriﬁ  es lecithin and FC on both HDL-C and Apo B 
lipoproteins. The phospholipid component of HDL-C appears to 
mediate binding to LCAT, while the apolipoprotein component 
activates the enzyme (Furbee et al 2002). Recent evidence 
suggests that increased glycation of Apo A1 in subjects with 
diabetes progressively decreases the rate of LCAT-mediated 
cholesterol esteriﬁ  cation (Nobecourt et al 2007).
Familial LCAT deﬁ  ciency (FLD) and ﬁ  sh-eye disease 
(FED) are distinct inherited syndromes associated with absent 
or impaired LCAT expression, respectively. Low HDL-C lev-
els and corneal opaciﬁ  cation characterize both diseases, while 
individuals with FLD also suffer from anemia and renal fail-
ure. Variable degrees of premature atherosclerosis have been 
observed in these populations (Funke et al 1991). Conversely, 
over expression of human LCAT in transgenic animal models 
correlates with a 7-fold increase in serum HDL-C, increases 
in Apo AI levels, and a marked reduction in atheromatous 
plaque burden (Francone et al 1990). These ﬁ  ndings suggest 
that LCAT over expression may serve as a novel therapeutic 
target in the prevention and treatment of CHD.
Phase three: cholesterol ester 
transfer protein (CETP) mediates 
exchange of cholesterol esters 
between HDL-C and Apo B 
lipoproteins
The enzyme cholesteryl ester transfer protein (CETP) 
exchanges CE from HDL-C for TG in LDL-C and VLDL. 
Newly acquired CE in VLDL and LDL-C is then taken up by 
the hepatic LDLr for excretion as bile (Morton and Greene 
1997). Found predominantly in the liver, spleen, and adipose 
tissue, expression of CETP is enhanced by hypercholester-
olemic diets via activation of a sterol regulatory protein and 
through binding of oxysterols to the LXR/RXR receptor 
(De Grooth et al 2004).
Heritable CETP deﬁ  ciencies in the Japanese population 
are associated with signiﬁ  cant increases in large HDL-C 
particles and smaller LDL-C particles with a lower afﬁ  n-
ity for LDL-C receptors (Inazu et al 1990). Heterozygotes 
with a 40% decrease in CETP levels had a mean increase in 
HDL-C of 30% and no signiﬁ  cant change in LDL-C levels, 
while homozygotes with complete loss of CETP levels had 
a greater than 100% increase in HDL-C and 40% decrease 
in LDL-C and Apo B levels (Inazu et al 1990; Koizumi 
et al 1991). Despite these ﬁ  ndings the correlation between 
low CETP levels and reduced CHD risk remained elusive 
as heterozygotes deﬁ  cient in CETP continue to manifest 
atherosclerotic coronary disease (Hirano et al 1995).
Two population studies have associated high CETP levels 
with an increased risk of CHD. A nested case control study 
known as the European Prospective Investigation into Can-
cer and nutrition (EPIC)-Norfolk cohort study suggested an 
increased CHD risk in patients with elevated TG and elevated 
CETP levels (Boekholdt et al 2004). Data from the Regres-
sion Growth Evaluation Statin Study (REGRESS) (Klerkx 
et al 2004) study also associated high CETP levels and 
rapid progression of established CHD in men. In this study, 
treatment with pravastatin signiﬁ  cantly improved lipid and 
angiographic parameters in patients with high baseline CETP 
independent of baseline lipids, suggesting plasma CETP 
levels may be a marker of response to statin therapy.
The role of CETP in modulating atherogenesis is complicated 
by dual pro-atherogenic and anti-atherogenic effects of 
transferring CE and TG between lipoproteins (Figure 2).
Potential proatherogenic properties of CETP activity 
include: 1) TG-laden HDL-C particles may undergo enhanced 
renal excretion thereby reducing total circulating HDL-C 
levels and RCT, 2) CE-laden VLDL and LDL-C particles 
may be acquired by peripheral macrophages and promote 
atherosclerosis, and 3) CETP also transfers TG from VLDL 
to LDL-C thereby generating small atherogenic LDL particles 
(Hirano et al 2000; Barter et al 2003).
However, complete abolition of CETP activity results in 
large, cholesterol-laden, dysfunctional HDL-C with reduced 
cholesterol efﬂ  ux RCT capacity (Yamashita et al 1988; Sakai 
et al 1991; Ikewaki et al 1995). Furthermore, CETP activity Vascular Health and Risk Management 2008:4(1) 44
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may be anti-atherogenic if CE-laden lipoproteins are bound by 
the LDLr for hepatic uptake and excretion. CETP activity may 
promote RCT by stimulating LCAT activity and regenerating 
pre-β HDL (Brewer et al 2004). For this reason, partial inhibi-
tion of CETP activity has been the focus of novel therapeutic 
strategies employing CETP inhibition as discussed below.
Phase four: HDL-C catabolism
As CE accumulate in its central core, pre-β HDL-C matures 
into larger HDL-C particles known as HDL-3 and HDL-
2. These larger molecules undergo hepatic catabolism 
and excretion in bile. HDL-C catabolism is mediated by 
4 mechanisms: 1) hepatic uptake of larger HDL-C particles 
via hepatic scavenger receptor B1 (SR-B1) receptors for 
excretion as bile, 2) metabolism of mature HDL-C by hepatic 
lipase (HL) to smaller particles devoid of lipid and rich in Apo 
AI, 3) renal uptake of smaller HDL-C particles mediated by 
apo-E receptors such as cubulin, or 4) LDLr-mediated hepatic 
uptake of LDL-C and VLDL-C after acquiring CE via CETP 
activity (Moestrup and Koz 2000; Lewis 2006).
Pleiotropic effects of HDL-C: 
beyond RCT
The vasoprotective properties of HDL-C extend beyond 
its ability to initiate RCT (Figure 3). Substantial evidence 
supports the contention that HDL-C and Apo AI prevent 
oxidative damage, inhibit systemic inﬂ  ammation, promote 
vascular reactivity and integrity, and prevent thrombosis 
(Hayek et al 1995; Watson 1995; Navab et al 1996; 
Bonnefant-Rousselot et al 1999; Mineo et al 2006).
Antioxidant effects of HDL-C
The major anti-oxidant effects of HDL-C are mediated 
by two associated enzymes paroxonase (PON) and 
platelet-activating factor acetylhydrolase (PAFAH) (Graham 
et al 1997). PON, an arylesterase enzyme carried by Apo AI, 
inhibits oxidation of LDL-C (Mackness et al 2000). LDLr-
null mice lacking PON are susceptible to organophosphate 
toxicity and manifest accelerated atherosclerosis (Shih et al 
1998). In epidemiologic studies, genetic polymorphisms of 
the PON gene may be associated with an increased risk of 
CHD (Hegele 1999).
Platelet activating factor (PAF) is a potent phospholipid 
released by activated endothelial cells. PAF promotes cell 
adhesion, platelet aggregation, and vascular permeability. 
HDL-C inhibits PAF production by endothelial cells in 
dose-dependent manner (Sugatani et al 1996) via hydrolysis 
of acetyl residues mediated by PAFAH. Genetic polymor-
phisms of the enzyme PAFAH have been associated with 
an increased risk of acute MI (Liu et al 2006). PAFAH also 
Figure 2 Dual nature of CETP activity. By shuttling cholesteryl esters (CE) and triglycerides (TG) between HDL-C and Apo B-associated lipoproteins, the enzyme cholesteryl 
ester transfer protein (CETP) creates substrate for both pro-atherogenic and anti-atherogenic pathways.
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degrades oxidized LDL-C and inhibit oxidation of LDL-C 
(Mackness et al 2004; Arakawa et al 2005).
Anti-inﬂ  ammatory effects of HDL-C
The role of inﬂ  ammation in atherogenesis has been well-
established by a number of studies demonstrating accumulation 
of macrophages derived from circulating monocytes in 
atheromatous plaques. Anti-inﬂ  ammatory effects of HDL-C 
include: 1) neutralization of lipopolysaccharide-induced 
tumor necrosis factor alpha (TNF-α) release, 2) inhibition 
of complement activation, 3) inhibition of vascular cell 
adhesion molecules (VCAM) and monocyte chemotactic 
protein (MCP-1), which are known to mediate monocyte-
endothelial cell interaction, and 4) induced expression of the 
anti-inﬂ  ammatory cytokine transforming growth factor-beta 
2 by HDL-3 (Dimayuga et al 1999; Shah et al 2001; Calabresi 
et al 2003; Barter et al 2004; Norata et al 2005).
Effects of HDL-C on endothelial function 
and integrity
In patients with known CAD, elevation of HDL-C 
levels via pharmacologic therapy improves endothelial 
function (O’Connell et al 2001). In patients with 
CHD, HDL-C levels correlate positively with coronary 
vasomotor tone (Zeiher et al 1994). In vitro, HDL-C 
enhances endothelial nitric oxide synthase (eNOS) 
activity (Kuvin et al 2002). The mechanism of HDL-C 
mediated eNOS activation remains unknown, however 
may involve an interaction between endothelial SR-B1 
and Apo AI (Yuhanna et al 2001). In a murine model 
of myocardial infarction, exogenous administration 
of human HDL-C increases myocardial perfusion as 
measured by 99mTc-MIBI uptake via NOS-dependent 
mechanisms (Levkau et al 2004).
HDL-C also enhances endothelial integrity. HDL-C 
inhibits endothelial apoptosis induced by TNF-α in a 
dose-dependent manner by inhibiting caspase 3 activity 
(Sugano et al 2000). HDL-associated lysosphingolipids 
also suppress mitochondrial pathways of apoptosis by 
activating the anti-apoptotic serine/threonine protein 
kinase, Akt (Nofer et al 2001). HDL-C also promotes 
endothelial cell proliferation via a mechanism involving 
increased phospholipase C activity (Darbon et al 1986; 
Honda et al 1999).
Figure 3 Approaches to enhance HDL-C levels and activity.
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Antithrombotic effects of HDL-C
HDL-C is also associated with anti-thrombotic and pro-
ﬁ  brinolytic effects. HDL-C inhibits platelet aggregation by 
blocking thromboxane-A2 (TXA2) and PAF activity, while 
stimulating nitric oxide (NO) and PGI2 synthesis (Saku et al 
1985; Naqvi et al 1999). In the Atherosclerosis Risk in Com-
munities (ARIC) study, HDL-C levels inversely correlated 
with circulating von Willebrand factor (vWF) levels, suggest-
ing that HDL-C may prevent synthesis of this pro-thrombotic 
protein. HDL-C also enhances the anti-thrombotic activity 
of protein C and protein S (Grifﬁ  n et al 1999). HDL-C may 
also attenuate the activity of tissue factor, a potent stimulant 
of the extrinsic coagulant pathway (Carson 1981).
Taken together, the pleiotropic effects of HDL-C suggest 
that its use either as a supplement or an infusion may not be 
limited to chronic therapy, but may eventually play a role in 
the acute management of vascular disorders. To date, exog-
enous infusions of synthetic HDL-C have been effective in 
animal models of atherosclerosis (Shah et al 2001), restenosis 
after angioplasty (Ameli et al 1994), vascular thrombosis 
(Li et al 1999), myocardial ischemia-reperfusion injury 
(Calabresi et al 2003), and septic shock (McDonald et al 
2003). Approaches to raise HDL-C levels and subsequently 
promote RCT include lifestyle modiﬁ  cations, standard phar-
macologic therapy, and several emerging therapeutics based 
on metabolic targets involved in RCT (Figure 3).
Approaches to raising HDL-C levels: 
lifestyle modiﬁ  ctions
Exercise and weight loss
Numerous studies associate excess body weight with higher 
TC, LDL-C, and TG levels and lower HDL-C levels. Active 
weight loss improves HDL-C levels, while decreasing 
LDL-C levels (8% decrease for every 1 kg of weight lost). A 
meta-analysis of 70 studies examining the effects of weight 
reduction on lipid proﬁ  les published between 1966 and 1989 
demonstrated a 1 mg/dL increase in HDL-C for every 3 kg of 
weight lost (Dattilo et al 1992). A one-year randomized con-
trolled study evaluating weight loss on plasma lipid proﬁ  les 
in 131 overweight sedentary men demonstrated a signiﬁ  cant 
increase in plasma HDL-C levels (44 mg/dL with exercise, 47 
mg/dL with diet, versus 40 mg/dL in controls; p   0.01), while 
LDL-C levels remained unchanged (Wood et al 1998).
As a means to reducing weight, regular aerobic exercise 
increases HDL-C by 10%–20% on average in sedentary 
adults (Williams 1997). Previous studies report an increase in 
HDL-C levels by 1 mg/dL for every 4 to 5 miles run per week 
(ie, 49 mg/dL with 5 miles (8 km) run per week, 51 mg/dL 
with 9 miles (15) run per week, 53 mg/dL with 12 miles 
(20 km) run per week, and 57 mg/dL with 31 miles (50 km) 
run per week; p   0.001 versus non-runners) (Kokkinos et al 
1995). While exercise quantity and intensity differ between 
studies, the duration of aerobic exercise rather than intensity 
appears to have a greater impact on HDL-C levels (Durstine 
et al 2001).
Variable changes in HDL-C have been observed in 
response to exercise. Some individuals signiﬁ  cantly increase 
HDL-C levels after 8 weeks of regular aerobic exercise (run-
ning), while other individuals may not manifest changes in 
HDL-C for nearly 2 years (Durstine et al 2001). In another 
study, no signiﬁ  cant change in HDL-C was observed in 
adults with low HDL-C and moderately elevated LDL-C 
after 6 weeks of walking or jogging 10 miles (16 km) per 
week (Stefanick et al 1998). Moreover, women appear to 
experience greater improvement in HDL-C with cardiac reha-
bilitation than men (Savage et al 2004). In general, HDL-C 
increases with exercise supporting the recommendation of a 
program of regular, brisk aerobic exercise program most days 
of the week (US Department of Health and Human Services 
1999). The mechanisms, by which exercise and reduced 
weight increase HDL-C likely involves enchanced lipopro-
tein lipase (LL) activity, increased RCT, and increased levels 
of pre-β HDL (Gupta et al 1993; Sviridov et al 2003).
Dietary modiﬁ  cations
Major dietary inﬂ  uences on HDL-C levels include total fat 
intake (independent of fat type), trans – fatty acids, and 
alcohol intake (Thornton et al 1983; Rossner and Bjor 1987; 
Lichtenstein 1999). A low saturated fat diet lowers both 
LDL-C and HDL-C. In a recent study, 11 healthy volunteers 
were randomized to either a low fat diet (19% fat) or a high fat 
diet (50% fat) (Meksawan et al 2004). Individuals consuming 
a low fat diet had a signiﬁ  cantly (p   0.05) lower HDL-2 
subpopulation (54 ± 3 vs 63 ± 3 mg/dL) and Apo AI (118 ± 
4 vs 127 ± 3 mg/dL) compared with subjects consuming a 
high fat diet. In addition, reduced dietary fat has been shown 
to signiﬁ  cantly decrease HDL-C2 fractions, which has been 
linked to antiatherogenic effects of HDL-C (Berglund et al 
1999). This suggests that low fat diets may adversely affect 
the most antiatherogenic HDL subpopulation. However, a 
simultaneous decrease in LDL-C with low fat diets appears 
to be more clinically important than the reduction in HDL-C 
levels.
High consumption of n-3 polyunsaturated fatty acids 
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ated with higher HDL-C/Apo AI ratios and increased 
cholesterol efﬂ  ux from cellular membranes to HDL-C 
(Gerasimova et al 1991). Consumption of foods high in 
n-3 polyunsaturated fats (cold-water ﬁ  sh, some shellﬁ  sh, 
as well as ﬂ  ax seed, canola, soybean oils and walnuts) 
increase HDL-C. However, the ability of n-3 polyunsatu-
rated fats to raise HDL-C maybe inﬂ  uenced by TG levels. 
Dietary modiﬁ  cation with omega-3 fatty acids (ﬁ  sh oil), 
such as eicosapentaenoic acid and docosahexaenoic acid, 
leads to signiﬁ  cant reductions in VLDL-C (25%–30%) 
and triglyceride levels, yet exerts only a modest effect 
on HDL-C levels (0 to 3% increase) in patients with TG 
levels above approximately 175 mg/dL (Kris-Etherton et al 
2002). This suggests that optimization of an individuals 
TG must occur before a clinically signiﬁ  cant increase in 
HDL-C in response to a diet high in n-3 polyunsaturated 
fats is observed.
Moderate alcohol consumption has been shown to elevate 
HDL-C levels (Ellison RC 2004). Mechanisms by which 
alcohol consumption increases HDL-C may involve changes 
in Apo AI synthesis and transportation, inhibition of CETP 
activity and stimulation of early steps in RCT (Van der 
Gaag et al 2001). A meta-analysis of 25 studies found that 
consumption of 30 g of alcohol per day increases HDL-C by 
about 4 mg/dl, irrespective of the type of alcohol consumed. 
With weighted regression, this represents a 0.133 mg/dL 
increase in HDL-C per gram of alcohol consumed per day, 
an 8% increase from pre-treatment levels (Rimm et al 1999). 
Similarly, in a review of 340 MI patients presenting with MI, 
alcohol consumption was strongly associated with increased 
HDL-C and a signiﬁ  cantly reduced relative risk of MI in 
the two highest consumption categories ( 1 drink/day and 
3 drinks/day) (Gaziano et al 1993). Mild to moderate alcohol 
consumption (1–2 alcoholic beverages several days a week) 
is reasonable for those individuals with low HDL-C. Cau-
tion should be used, however, when recommending alcohol 
consumption as a therapeutic mechanism in populations at 
risk for alcohol abuse.
A recent study suggests that the greatest improvement in 
HDL-C for both men and women in response to weight loss, 
exercise, and alcohol consumption was seen in individuals 
within the highest percentiles of HDL-C at baseline, with 
lower levels of baseline HDL-C being more resistant to 
lifestyle modiﬁ  cations (Williams 2004). Separating the effect 
of one lifestyle modiﬁ  cation from another on HDL-C is dif-
ﬁ  cult. For instance, increases in HDL-C with exercise may 
be due to the resultant weight loss or gene-environmental 
interactions (Miller et al 2003).
Smoking cessation
Cigarette smoking is associated with lower HDL-C levels 
(Craig et al 1989). The mechanisms by which cigarette 
smoking lowers HDL-C remain unclear. Cigarette smokers 
have signiﬁ  cantly lower LCAT activity (Imamura et al 2002) 
and exhibit changes in lipid transfer proteins and CETP 
activity compared to non-smokers (Freeman et al 1998; 
Mero et al 1998). In a meta-analysis of 29 studies HDL-C 
levels were signiﬁ  cantly increased after smoking cessation, 
more so in women and to a greater extent in individuals with 
higher baseline HDL-C ( 1.2 mmol/L) (Maeda et al 2003). 
Moffatt and colleagues demonstrated women smokers have 
15%–20% lower HDL-C levels compared to non-smokers 
(p   0.05); the HDL-C values improved to normal levels 
within 30–60 days of smoking cessation (Moffatt 1988). 
Using a comprehensive approach to smoking cessation 
(wellbutrin/nicotine-replacement/counseling) remains an 
important recommendation for those individuals with low 
HDL-C. Despite the complexity of lifestyle modiﬁ  cations 
on HDL-C, patients with low HDL-C should be encour-
aged to become physically active on a regular basis, stop 
smoking, obtain stable weight reduction with a BMI  25, 
and increase consumption of polyunsaturated and mono-
unsaturated fats.
Approaches to raising HDL-C levels: 
standard pharmacotherapy
While dietary and lifestyle modiﬁ  cations can raise HDL-C 
levels, their effect on cardiovascular outcomes may result 
from beneﬁ  cial effects on non-HDL-C lipid components such 
as LDL-C. At present, standard pharmacotherapy to raise 
HDL-C levels includes niacin, ﬁ  brates, and statins.
Niacin
Since 1955, the B-vitamin niacin (nicotinic acid) has been 
used in the treatment of dyslipidemia (Altschul et al 1955). 
Niacin is the most useful pharmacologic therapy for raising 
HDL-C levels; it has been shown to increase HDL-C by 35%, 
while lowering TG levels by 20%–50% and LDL-C levels by 
5%–25% (Szapary and Rader 2004). Niacin raises HDL-C 
levels by reducing the fractional catabolic rate of Apo AI 
containing HDL-C particles, decreasing hepatic removal of 
lipoprotein A-I (LpA-I) (a cardioprotective subfraction of 
HDL-C without Apo AII), and inhibiting removal of Apo 
AI without affecting HDL cholesterol ester (Jin et al 1997); 
resulting in an increase of Apo AI enriched, pre-β HDL 
particles (Ganji et al 2003). Using carotid intima-medial 
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a randomized, placebo-controlled study of extended release 
niacin in addition to statin therapy in 167 patients with 
known CAD and low serum HDL-C ( 45 mg/dL) showed a 
signiﬁ  cantly reduced rate of IMT progression in individuals 
without insulin resistance (p = 0.026) (Taylor et al 2004). An 
upcoming study known as ARBITER 6-HALTS (HDL and 
LDL Treatment Strategies) will randomize 400 subjects with 
coronary heart disease to HDL-C (extended-release niacin) 
and LDL-C (ezetimibe) focused strategies of lipid therapy 
and will measure changes in mean CIMT after 14 months 
(Devine et al 2007).
Fibrates
Fibric acid derivatives (ﬁ  brates) reduce CHD risk in patients 
with baseline LDL:HDL-C ratios of  5.0 (Huttunen 1991). 
Fibrates slow the progression of coronary atherosclerosis 
and reduce coronary events (Ericsson et al 1996; Frick et al 
1997). Fibrates induce a 5%–20% increase in HDL-C, with 
generally modest reductions in LDL-C and a pronounced 
reduction in triglyceride-rich lipoproteins (Despres 2001).
Fibrate therapy increases HDL-C levels by activating 
PPARα and by enhancing expression of Apo AI and AII, LL, 
and ABCA1, which collectively enhance RCT (Tilly-Kiesi 
et al 1992). By inducing LL activity, ﬁ  brates also increase 
hepatic fatty acid uptake, enhance removal of LDL particles, 
and reduce lipid exchange between VLDL and HDL (Staels 
et al 1998). The hypotriglyceridemic effects of ﬁ  brate therapy 
result from enhanced LL activity and inhibition of Apo CIII 
gene expression by fibrate-mediated PPARα activation 
(Staels et al 1995; Motojima et al 1997).
Depending on baseline lipid proﬁ  les and the potency of 
individual ﬁ  brates, variable effects on HDL-metabolism have 
been observed. Despite a greater than 15% increase in HDL-C 
levels with bezaﬁ  brate therapy, the Bezaﬁ  brate Infarction 
Prevention (BIP) failed to demonstrate a signiﬁ  cant reduc-
tion in the primary composite end point of fatal or nonfatal 
MI or sudden death (Goldbourt et al 1993). In contrast, in 
the VA-HIT study, gemﬁ  brozil increased HDL-C on average 
by 7.5% with a 2% reduction in risk correlated with every 
1% increase in HDL-C (Rubenset al 2001). Similarly, in the 
Lopid Coronary Angiography Trial (LOCAT), gemﬁ  brozil 
slowed progression of coronary atherosclerosis and the for-
mation of bypass graft lesions.
Statins
Statins inhibit HMG-CoA reductase, the rate-limiting step in 
cholesterol biosynthesis, resulting in increased LDLr density 
with decreases in LDL, IDL, and VLDL particle synthesis 
(Farnier 1998; Segrest et al 2000). Subsequent reductions in 
LDL-C and TG concentrations are the primary antiatherogenic 
properties of statins (Harper and Jacobsen 1999). Statins reduce 
LDL-C levels by 25%–35% at low to moderate doses, which 
correlates with a reduction in relative risk of coronary events 
by 25%–37% (Sacks et al 1996; West of Scotland Coronary 
Prevention Group 1996; Long-Term Intervention with Pravas-
tatin in Ischaemic Disease (LIPID) Study Group 1998).
Statins increase HDL-C by 5%–15% and decrease TG 
levels by 7%–30% (Belalcazar et al 1998). The mechanism 
of statin-induced increases in HDL-C remains incompletely 
understood. Some studies suggest increased HDL-C results 
from a decreased fractional catabolic rate of Apo AI and an 
increased production of Apo AI induced by inhibiting HMG-
Co A reductase (Schaefer et al 1999). Statins have also been 
shown to increase Apo AI levels by inhibiting the Rho-A 
kinase signal transduction pathway, resulting in activation 
of PPARα (Martin et al 2001).
Statins may also reduce hepatic lipase activity, resulting 
in enhanced synthesis of mature HDL-C. Another potential 
mechanism for increased HDL-C levels in response to statin 
therapy is by inhibiting CETP activity. A study of patients 
with the “B1” variant of the CETP gene showed high levels 
of baseline CETP activity and low levels of HDL-C with 
corresponding progression of atherosclerosis. Treatment with 
pravastatin abolished the progression in atheromatous burden 
and non-signiﬁ  cantly increased HDL-C levels in patients with 
the “B1” variant (Kuivenhoven et al 1998).
Of the available statins, simvastatin, rosuvastatin, and ﬂ  u-
vastatin more effectively raise HDL-C levels compared with 
atorvastatin at doses that lead to similar reductions in LDL-C. 
In a 36-week, multicenter, double-blind, dose titration study, 
826 patients with LDL-C  160 mg/dL and triglyceride 
 350 mg/dL were randomized to receive titrated doses of 
simvastatin (maximum 40 mg/day) or atorvastatin (maximum 
40 mg/day) over 6–12 weeks. Signiﬁ  cantly greater increases 
in HDL-C and Apo AI with simvastatin compared to atorv-
astatin (HDL-C: 9% vs 7% p   0.001; Apo AI: 6% vs 3%, 
p   0.001) were observed (Kastelein et al 2000). Independent 
clinical studies have shown that 40 mg/day of simvastatin 
increase HDL-C by approximately 7%–9% versus a 4%–5% 
increase with 20 mg/day of atorvastatin (Heinonen et al 1996; 
Crouse et al 1999). Generally niacin is more effective than 
statins alone in raising HDL-C levels.
Combination therapy
Combination therapy using statins with niacin or ﬁ  brates has 
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2002). The HDL Atherosclerosis Treatment Study (HATS) 
studied the combination of statin plus extended-release 
niacin in 160 patients with known CAD, low serum HDL-C 
levels ( 35 mg/dL in males and  40 mg/dL in females), 
LDL-C levels  145 mg/dL, and TG levels  400 mg/dL. 
After 3 years of follow-up, combination therapy increased 
HDL-C levels by 26%, reduced LDL-C levels by 42%, 
induced regression of the average coronary stenosis by 0.4% 
(p   0.001) and reduced cardiovascular events by greater 
than 60% (Brown et al 2001).
Reﬂ  ecting the ability of statins and ﬁ  brates to synergisti-
cally activate PPARα, statin-ﬁ  brate combinations have been 
evaluated in a number of clinical trials (Ellen and McPherson 
1998; Papadakis et al 1999; Farnier et al 2000; Athyros et al 
2002; Vega et al 2003; ). A multi-center, double-blind trial 
of 333 patients using ﬂ  uvastatin compared to bezaﬁ  brate 
versus a combination of the two agents for 24 weeks showed 
a signiﬁ  cant decrease in LDL-C levels in treatment groups 
receiving ﬂ  uvastatin compared to bezaﬁ  brate alone. Further-
more, HDL-C levels were signiﬁ  cantly elevated with bezaﬁ  -
brate alone or in combination with ﬂ  uvastatin compared with 
ﬂ  uvastatin alone (p   0.001). The combination of ﬂ  uvastatin 
and bezaﬁ  brate was well tolerated and signiﬁ  cantly increased 
HDL-C (22%), decreased LDL-C (24%), and decreased TG 
levels (38%) compared with ﬂ  uvastatin alone (p   0.001) 
(Pauciullio et al 2000).
Recently, the Comparative Effects on Lipid Levels 
(COMPELL) trial determined the relative efﬁ  cacy of combi-
nation therapy with a statin and niacin or ezetimibe compared 
with a statin alone over 12 weeks. Coadministration of niacin 
(500 mg up-titrated to 2000 mg) with atorvastatin (20–40 mg, 
n = 60) or rosuvastatin (10–20 mg, n = 65) decreased LDL-C 
by 56% and 51% and increased HDL-C by 22% and 24% 
respectively (p = NS). While simvastatin plus ezetimibe 
decreased LDL-C by 57%, HDL-C only increased by 10% 
compared to baseline. Rosuvastatin (10–40 mg) monotherapy 
decreased LDL-C by 53% and raised HDL-C by 7% (Jones 
2006). Future studies involving rosuvastatin/fenoﬁ  brate 
combination therapy and the recently announced combi-
nation of rosuvastatin with a next generation fenoﬁ  brate 
(ABT-335) will provide further insight into the efﬁ  cacy of 
dual-targeted therapy.
Approaches to raising HDL-C levels: 
emerging therapeutics
Based on preclinical data, multiple strategies to enhance the 
beneﬁ  cial effects of HDL-C are being considered. HDL-C 
delipidation therapy (Kostner et al 2002), exogenous Apo AI 
mimetics (Navab et al 2004), CETP inhibition (Brousseau 
et al 2004), LXR/RXR agonists (Brewer et al 2004), selective 
and non-selective PPAR agonists (Oliver et al 2001; Schmitz 
et al 2002), and drugs targeting HDL-C catabolism (Mezdour 
et al 1997; Jansen et al 2004) are among some of the novel 
emerging therapies harnessing the anti-atherogenic, anti-
oxidant, anti-inﬂ  ammatory, and pro-endothelial functions 
of HDL-C.
HDL-C delipidation therapy
Selective HDL-C delipidation therapy utilizes plasmapher-
esis whereby extracted plasma is mixed with a delipidating 
agent and separated into an inorganic and organic phase. 
The organic component contains a high concentration of 
delipidated HDL, similar to lipid-poor pre-β HDL produced 
by the liver, which is then returned to the circulation. In 
a series of animal studies delipidation therapy has been 
shown to markedly increase circulating pre-β HDL levels 
and subsequently increase ABCA1-mediated cholesterol 
efﬂ  ux from peripheral cells without exerting a signiﬁ  cant 
effect on LDL-C metabolism Animal studies evaluating 
delipidation therapy followed by intravascular ultrasound 
assessment of vascular plaque progression or regression are 
ongoing (Shah 2007).
Exogenous administration of Apo AI 
and Apo AI mimetics
Exogenous administration of Apo AI directly enhances RCT 
via the ABCA1 pathway (Zhang et al 2003; Navab et al 2004; 
Arakawa et al 2004). Treating normal human LDL-C with 
exogenous Apo AI in vitro reduces levels of oxidized lipids 
by 50%–60% and prevents monocyte chemotactic activity, a 
primary step in atherogenesis (Poon et al 1997). Exogenous 
administration of Apo AI-associated lecithin discs reduces 
the ability of LDL to induce monocyte chemotaxis, increases 
concentrations of pre-β HDL, and stimulates RCT in 
human subjects (Nanjee et al 2001). Apo AI infusions also 
modulate phospholipids transfer protein (PLTP), LCAT, and 
CETP activity, all of which potentially contribute to RCT 
(Kujiraoka et al 2003).
Recently, Tardiff and colleagues administered 4 weekly 
infusions of a mixture of human wild-type Apo AI and 
soybean phosphatidylcholine (CSL-111; 40 mg/kg or 
80 mg/kg) or volume-matched placebo to 183 patients 
presenting with an acute coronary syndrome as part of the 
Effect of reconstituted HDL on Atherosclerosis – Safety 
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infusion, intravascular ultrasound (IVUS) and quantitative 
coronary angiographic (QCA) measurements were 
compared to baseline. Patients receiving CSL-111 
experienced a –3.4% change in atheroma volume (p = 0.48 
vs placebo; p   0.001 vs baseline) with an absolute 
change of –5.3 mm3 (p = 0.39 vs placebo; p   0.001 vs 
baseline). Notable, transient liver function abnormalities 
were observed in the CSL-111 group versus placebo. One 
patient developed a 100-fold increase in ALT levels in the 
high dose (80 mg/kg) infusion group (Tardif et al 2007) 
While the primary endpoint of the study was negative, 
the data presented suggest a potential beneﬁ  t for inducing 
plaque regression. This study highlights the complexity 
surrounding exogenous Apo AI therapy.
Based on observations in a family with low HDL-C and a 
lack of atherosclerotic disease from Limone sul Garda, Italy, 
a variant form of Apo AI, known as Apo AI Milano (AIM), 
was identiﬁ  ed in 1980 (Franceschini et al 1980). A cysteine-
arginine substitution at position 173 in the amino acid 
sequence allows the mutant protein to form disulﬁ  de bonds 
with other Apo AI molecules and Apo AII. AIM homodimers 
and heterodimers may enhance cholesterol efﬂ  ux thereby 
augmenting RCT (Chiesa et al 2002).
Administration of recombinant Apo AI Milano (rAIM) 
reduces plaque cross sectional area compared to saline-
placebo by up to 40% in rabbit carotid models of athero-
sclerosis (Ameli et al 1994; Ibanez 2007). Similar results 
have been demonstrated in balloon injured arteries in 
hypercholesterolemic rabbits, Apo E-deﬁ  cient mice, and in 
transgenic mouse models of Apo AI over-expression (Rubin 
et al 1991; Shah et al 1998). Exogenous HDL-C or Apo AI 
administration also enhance fecal steroid excretion, increase 
serum pre-β HDL, and enhance RCT in humans (Westman 
et al 1995; Eriksson et al 1999).
In 2003 a landmark study using rAIM (ETC-216) quanti-
ﬁ  ed coronary plaque volume as a response to pharmacologic 
intervention with intravascular ultrasound (IVUS). This study 
evaluated the effect of exogenous administration of ETC-216 
on coronary atherosclerosis in patients with acute coronary 
syndromes. ETC-216 reduced total atheroma volume by 
1.3% (39.7–38.4) and 0.7% (37.2–36.6) in the moderate 
and high dose treatment groups respectively, while a 0.14% 
(34.8–34.9) increase was noted in the placebo group (Nissen 
et al 2003). This “proof-of-concept” study demonstrated the 
ability of Apo AI mimetic peptides to halt progression and 
potentially induce regression of atheromatous plaque.
A series of Apo AI mimetic peptides are currently 
under investigation. ETC-642 is a second generation Apo 
AI synthetic peptide containing three charged residues in a 
22 amino-acid sequence, rendering the peptide more hydro-
phobic (Navab et al 2005). Within hours of treatment with 
ETC-642 increased HDL-C serum levels have been observed 
in rabbit models. Increased CE content in HDL-C indicates 
concomitant LCAT activation by ETC-642. This rapid eleva-
tion of HDL-C levels suggests a possible future role for Apo 
AI mimetic peptides in the management of acute coronary 
syndromes or in the setting of ischemia-reperfusion injury 
(Marchesi et al 2004).
Another Apo AI mimetic peptide known as D4F reduces 
atherosclerosis in mouse models (Garber et al 2001). Peptide 
D4F contains 18 amino acids in a class A amphipathic helix 
with polar and non-polar faces yielding high lipid afﬁ  nity 
(Datta et al 2001). D4F enhances the anti-inﬂ  ammatory 
properties of HDL-C, reduces LDL-mediated monocyte che-
motaxis, reduces macrophage migration into atheromatous 
plaques, and reduces atherosclerosis in Apo E KO mice alone 
or in combination with statin therapy. Both oral and intraperi-
toneal administration of D4F signiﬁ  cantly reduced evolving 
atherosclerotic lesions in vein grafts but not established 
atherosclerotic lesions in the aortic sinus, suggesting speciﬁ  c 
types of atherosclerotic lesions may modulate the beneﬁ  cial 
effects of Apo AI mimetic peptides (Li et al 2004).
Taking advantage of the amphipathic helical structure 
common to apolipoproteins, numerous Apo AI mimetic 
peptides are being developed. Unique helical conﬁ  guration 
with opposing hydrophobic and hydrophilic faces enhances 
interaction between lipid surfaces and apolipoproteins 
for the removal of membrane bound cholesterol. Some 
novel agents under development include: ETC-588 (large 
unilamellar vesicles – LUV), ETC-1001 (small molecule 
investigational product), helical peptides (Esperion 24218), 
and trimeric Apo-A (Proteopharma/Borean pharma) (Navab 
et al 2006).
Nuclear regulation of RCT: LXR 
and PPAR agonists
Liver X-receptors (LXR) are nuclear receptors that sense excess 
intracellular cholesterol (Wang and Briggs 2004). Hydroxyl-
ated cholesterol stimulates LXR-mediated transcription of 
ABCA1, which subsequently enhances RCT from peripheral 
tissues (Lund et al 2006). Two types of LXR receptors exist, 
LXRα and LXRβ. LXRα has been identiﬁ  ed in liver, intestine, 
macrophages and adipose tissues, while LXRβ is ubiquitously 
expressed similar to ABCA1 (Lala et al 2005).
LXR agonists prevent development of atherosclerosis 
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in rodent models. Non-selective LXR agonists increase 
ABCA1 synthesis with a gradual increase in HDL-C serum 
levels (Lund et al 2006). In a mouse LXRα knockout model, 
treatment with a non-selective LXR agonist increased 
HDL-C by day 7 with a less signiﬁ  cant increase in hepatic 
TG content (Joseph et al 2002). Similarly, treating LDLr 
KO mice with the LXR ligand, T-0901317, reduced 
atherosclerotic lesion development without affecting 
plasma total cholesterol levels (Terasaka et al 2003). 
Recently administration of the LXR agonist GW3965 to 
mice increased the rate of RCT from macrophages to feces 
in vivo (Naik et al 2006).
A major concern associated with LXR agonists is the 
development of hepatic steatosis. Since LXR agonists 
induce genes that stimulate lipogenesis, including the 
sterol response element binding protein (SREBP1-c) and 
fatty acid synthetase (FAS). The induction of these genes 
in the liver cause increased hepatic triglyceride synthesis, 
hypertriglyceridemia, and hepatic steatosis. Current 
research has focused on selective LXR modulators that may 
circumvent this adverse effect on hepatic function (Miao 
et al 2004).
First identiﬁ  ed in rodent models of ﬁ  brate-induced hepatic 
peroxisome proliferation, peroxisome proliferators activated 
receptors (PPARs) are another family of nuclear receptors 
closely linked to HDL-C metabolism (Everett et al 2000). Act-
ing as synthetic ligands for PPARα activation, ﬁ  brates increase 
circulating levels of HDL-C, enhance RCT and reduce vas-
cular inﬂ  ammation and thrombogenicity (Barbier et al 2002; 
Gervois et al 2007). PPARα agonists enhance gene expression 
of SR BI, Apo AI, Apo AII, LPL, and ABCA1 (Toth 2005). 
Statins also enhance PPARα activity and may enhance cho-
lesterol efﬂ  ux (Martin et al 2001; Inoue et al 2002).
Agents for the management of Type 2 diabetes such as 
thiazolidinediones are known PPARγ agonists and enhance 
ABCA1 mediated RCT and increase HDL-C levels in pri-
mates (Oliver et al 2001). PPARα and γ mediate activation 
of the LXR/RXR heterodimer, which in turn regulates cho-
lesterol efﬂ  ux via ABCA1 and ABCG1 activation (Schmitz 
et al 2002). Unfortunately, the development of novel PPAR 
agonists to date, particularly PPARγ and PPARα/γ,  have 
been halted due to preclinical and clinical adverse effects 
(Rubenstrunk et al 2007).
Cholesterol exchange transfer protein 
(CETP) inhibition
The complex relationship between CETP activity and ath-
erosclerotic disease has been illustrated by several recent 
studies evaluating CETP inhibition therapy. In the past, 
antisense oligodeoxynucleotides and antibodies against 
CETP increased HDL-C levels and reduced aortic athero-
sclerotic burden in cholesterol-fed rabbits (Sugano et al 
1998; Rittershaus et al 2000). In a phase II, randomized, 
placebo-controlled trial, 148 statin-naïve patients with mild 
hyperlipidemia were treated with a CETP inhibitor known 
as JTT-705. In this study, a 37% reduction in CETP activ-
ity correlated with a 34% increase in HDL levels and 7% 
decrease in LDL levels (De Grooth et al 2002).
Recently, the CETP inhibitor, torcetrapib, has been exten-
sively studied evaluated in a number of human trials. In a 
phase I, multi-dose study, torcetrapib was administered to 40 
normolipidemic individuals in doses of 10, 30, 60, and 120 mg 
per day and 120 mg twice daily. Signiﬁ  cant increases in serum 
HDL-C levels ranging from 16% to 91% (10 mg daily versus 
120 mg twice daily) with a decrease in LDL-C from 7% to 
42% (60 mg daily versus 120 mg twice daily) without chang-
ing TC levels was observed. At the highest dosing regimen, 
Apo AI and Apo E increased by 27% and 66% respectively, 
while Apo B decreased by 26% (Clark et al 2004).
Another single-blinded study compared torcetrapib alone 
at variable doses versus torcetrapib in combination with 
20 mg of atorvastatin for one month. HDL-C levels increased 
by 46%, 61%, and 106%, while LDL-C levels decreased 
by 17%, 7.5%, and 17% after treatment with 120 mg daily, 
120 mg daily plus 20 mg atorvastatin, and 120 mg twice 
daily respectively. No major adverse events were reported 
(Brousseau et al 2004).
Based on these promising findings, torcetrapib was 
evaluated in a large international clinical trial known as the 
Investigation of Lipid Level Management to Understand Its 
Impact in Atherosclerotic Events (ILLUMINATE). In this 
study, 15,000 patients at high risk for CHD received torcetra-
pib with atorvastatin versus atorvastatin alone. In December 
2006, this study was prematurely terminated due to an excess 
of deaths in the torcetrapib/atorvastatin versus atorvastatin 
groups (81 vs 51, respectively). Additionally, patients receiv-
ing torcetrapib had a higher incidence of heart failure, angina, 
and revascularization procedures. The adverse outcomes of 
the ILLUMINATE study may have been related to off-target 
effects of torcetrapib, such as an increase in systolic blood 
pressure (limited to 1–2 mmHg) or low levels of CETP inhi-
bition and reduced RCT (Honey 2007). Notably, inherited 
deﬁ  ciencies of CETP and other CETP inhibitor formulations 
did not increase systolic blood pressure, suggesting that the 
chemical structure of torcetrapib itself may have contributed 
to poor outcomes (Tall et al 2007).Vascular Health and Risk Management 2008:4(1) 52
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Two separate studies evaluated the impact of torcetrapib 
on atherosclerotic progression. The Investigation of Lipid 
Level Management Using Coronary Ultrasound to Assess 
Reduction of Atherosclerosis by CETP Inhibition and HDL 
Elevation (ILLUSTRATE) studied 1,188 patients with coro-
nary disease in a prospective, randomized, double-blinded 
fashion. Patients initially received atorvastatin monotherapy 
until LDL-C levels were below 100 mg/dL, after which time 
they were randomized to either atorvastatin (10–80 mg daily) 
monotherapy or atorvastatin plus 60mg torcetrapib daily. 
After 24 months, the torcetrapib/atorvastatin group had a 
61% relative increase in HDL-C and 20% decrease in LDL-C. 
However, no significant reduction in percent atheroma 
volume was observed between atorvastatin monotherapy 
and torcetrapib combination therapy (0.19% vs 0.12%, 
respectively). Torcetrapib therapy was again associated 
with a mean 4.6 mmHg increase in systolic blood pressure 
(Nissen et al 2007).
Further substantiating these ﬁ  ndings, the Rating of Ath-
erosclerotic Disease Change by Imaging with a New CETP 
Inhibitor (RADIANCE 1 and 2) trials, demonstrated no 
further reduction of atherosclerosis progression in carotid 
intima-media thickness after 24 months of therapy with 
atorvastatin versus atorvastatin/torcetrapib combination 
(Bots et al 2007; Kastelein et al 2007).
Summary
A considerable body of evidence supports the correlation 
between HDL-C levels and cardiovascular risk. However, 
trials evaluating HDL-C targeted therapies are limited, 
in part due to a lack of pharmacologic agents speciﬁ  cally 
designed to raise HDL-C and our limited ability to measure 
HDL-C effectiveness. As a result, there is not enough data 
to support guidelines recommending aggressive increases 
in HDL-C levels. With this in mind, evaluating the clinical 
efﬁ  cacy of emerging HDL-C targeted therapies will be of 
paramount importance.
Given the complexity of HDL-C metabolism, serum 
levels of HDL-C may not be an adequate indicator of 
efﬁ  cacy. At present, plasma HDL-C measurements have 
a ± 10% margin of error, which could lead to errors in 
measurement of up to 4 mg/dL (Friedewald et al 2007). 
The functional properties of circulating HDL-C levels, the 
kinetics of HDL-C metabolism, and the variable effects 
of HDL-C subfractions on atherogenesis are ignored 
by current laboratory measures of HDL-C (Forrester 
et al 2005). While measuring HDL-C subfractions are 
not recommended at present, recent data suggests that 
increased Apo AI plasma levels and Apo AI:Apo B ratios 
correlate with a reduced risk of myocardial infarction and 
stroke (Qureshi et al 2002).
As a crude marker of RCT, measuring sterol content in 
fecal matter indirectly reﬂ  ects the amount of cholesterol 
excreted by the liver as bile. Emerging therapies such as Apo 
AI mimetics (Eriksson et al 1999) and LXR agonists (Plosch 
et al 2002) increase fecal sterol excretion (FSE), while CETP 
inhibition with torcetrapib fails to affect fecal sterol content 
(Brousseau et al 2005). The clinical signiﬁ  cance of FSE as 
a marker of RCT remains uncertain.
At present, volumetric IVUS in combination with 
standard HDL-C measurement is our best measure of 
plaque stabilization or regression. Novel approaches using 
high-speed multislice CT, cardiac MRI, and intracoronary 
MRI may replace IVUS. Clinical trials using both sur-
rogate endpoints such as volumetric IVUS and carotid 
IMT in combination with hard clinical endpoints may 
be required to evaluate the efﬁ  cacy of emerging HDL-C 
based therapies.
During the next 10 years, many clinical trials will 
evaluate the effects of HDL-modiﬁ  cation therapy. While 
the past decade has focused on lowering levels of LDL-C 
and non-HDL-C to reduce atherosclerotic progression and 
CVD events, the next decade may prove that HDL-focused 
therapy induces regression of luminal atherosclerosis and 
improves CVD outcomes. We eagerly await the completion 
of the ongoing clinical trials employing a variety of novel 
strategies to raise HDL-C and possibly halt the progression 
of atherosclerotic vascular disease.
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